$5.6B global glaucoma market in for a shake-up; BMS hep C med loses FDA breakthrough rights; Actavis sells off acne med to Mayne Pharma;

> The $5.6 billion global glaucoma market is about to get a shake-up, as young companies such as Aerie Pharmaceuticals ($AERI) look to grab share for their own products. Story

> Bristol-Myers Squibb ($BMY) said its hepatitis C treatment daclatasvir is losing its FDA breakthrough therapy designation for genotype 1 patients, soon after Merck ($MRK) lost the breakthrough tag on its rival hep C cocktail. Story

> As it prepares to take over Allergan ($AGN) and its broad dermatology portfolio, Actavis ($ACT) is selling the U.S. rights to its Doryx acne treatment to Mayne Pharma for $50 million. Release

> Luitpold Pharmaceuticals is coming under fire from the FDA's Office of Prescription Drug Promotion for a promotional video for its iron-deficiency treatment Injectafer. Regulators say the video overstates its case for the drug and does not spell out its risks. Article (reg. req.)

> Healthcare professionals are venting on social media about U.K. cost watchdog NICE's new draft guidelines for diabetes meds, questioning in particular the agency's recommendations for Novo Nordisk's ($NVO) NovoNorm/Prandin tablets. Story

> ALK and bioCSL are teaming up to market ALK's allergy products in Australia and New Zealand. More

> John Kearney, Amgen's ($AMGN) U.K. and Ireland general manager, is taking over as president of the Association of the British Pharmaceutical Industry. Story

> Shares of Achillion Pharmaceuticals ($ACHN) climbed more than 11% Monday morning after the company announced promising results from a midstage clinical study of its experimental hepatitis C treatment. Article

> Michael du Toit has jumped ship at Publicis Healthcare Communications, where he was group co-chair, for the president's job at digital media company Everyday Health. Article (reg. req.)

And Finally… Pharma companies such as Biogen Idec ($BIIB) are using Twitter's promoted video feature to market products through social media. Story

Suggested Articles

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

As AZ and FibroGen have yet to submit the novel anemia drug to the U.S. regulators, national reimbursement talks are already underway in China.

Health and Human Services, hoping to resurrect a rule that would force drug prices into TV ads, appealed a judge's decision that blocked it.